



From Editor Desk

Dear Readers,

It gives me great pleasure to welcome you to the first issue of Volume 10 of the *IP Journal of Diagnostic Pathology and Oncology* (January–March 2025). As we embark on another year of academic excellence, this issue presents a diverse and enriching collection of articles that reflect the journal's core commitment to advancing research, diagnostics, and education in pathology and oncology.

This issue opens with a thought-provoking editorial, "Don't judge a book by its cover – Appearance can be deceptive", which offers a compelling reminder of the subtle interpretative challenges in histopathology and the importance of context in diagnosis.

The review articles are equally engaging, particularly the comprehensive exploration of resveratrol's therapeutic benefits and limitations in cancer, which bridges nutritional biochemistry and oncologic therapy. Another major highlight is the update on atypical meningioma, bringing forward clinicopathological insights into this WHO Grade 2 tumor that demands accurate diagnosis and vigilant follow-up. Additionally, the review on the emerging role of digital pathology and artificial intelligence provides a futuristic lens on cancer diagnostics, underlining how technology is transforming our field.


Our original research section includes a study on IgG4 expression in interstitial cystitis, adding valuable data from a tertiary care center, and a practical evaluation of HbA2 quantification using hemoglobin electrophoresis, relevant for thalassemia screening and diagnosis.

We also present an intriguing mix of rare and diagnostically challenging case reports—ranging from rhabdomyosarcoma of the nasal cavity and angiolymphoid hyperplasia in the inguinal region, to malignant mesothelioma and an atypical presentation of follicular thyroid carcinoma. These case studies serve as excellent learning resources for both trainees and practicing pathologists.

This issue also includes a short communication on the role of bortezomib in hematological malignancies, highlighting its therapeutic significance and evolving indications.

As we celebrate the journal entering its 10th volume, I extend my deepest gratitude to our authors, peer reviewers, editorial team, and readers for their sustained support and contributions. Let us continue fostering innovation, integrity, and collaboration in diagnostic pathology and oncology.

Happy reading...!



Dr. Indranil Chakrabarti

MBBS, MD, FIAC

Editor-in-Chief

IP Journal of Diagnostic Pathology and Oncology

Additional Professor

Dept. of Pathology

All India Institute of Medical Sciences, Kalyani, West Bengal, India

Email Id: drinch@rediffmail.com